NanoVibronix (NAOV) 10-Q/A 10 Jun 15 2015 Q1 Quarterly report (amended) Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2015	15-May-15
Document And Entity Information
Entity Registrant Name	NanoVibronix, Inc.
Entity Central Index Key	1326706
Document Type	10-Q
Document Period End Date	31-Mar-15
Amendment Flag	FALSE
Current Fiscal Year End Date	-19
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	No
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		2,611,328
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2015

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Mar. 31, 2015		Dec. 31, 2014
In Thousands, unless otherwise specified
CURRENT ASSETS:
Cash and cash equivalents	$2,796		$90
Trade receivables	18		21
Prepaid expenses and other accounts receivable	15		19
Inventories	29		35
Total current assets	2,858		165
PROPERTY AND EQUIPMENT, NET	16		18
DEFERRED ISSUANCE COSTS			358
SEVERANCE PAY FUND	177		182
Total assets	3,051		723
CURRENT LIABILITIES:
Accounts payable	89		101
Other accounts payable	345		702
Convertible Promissory notes	1,500		4,617
Total current liabilities	1,934		5,420
LONG-TERM LIABILITIES:
Warrants to purchase Common stock	709		734
Accrued severance pay	179		185
Total long-term liabilities	888		919
COMMITMENTS AND CONTINGENT LIABILITIES
STOCKHOLDERS' EQUITY (DEFICIENCY):
Stock capital - Common stock of $ 0.001 par value - Authorized: 24,000,000 shares at March 31, 2015 and December 31, 2014; Issued and outstanding: 380,247 and 163,580 shares at March 31, 2015 and December 31, 2014, respectively.		[1]		[1]
Additional paid-in capital	17,706		11,234
Accumulated deficit	-17,480		-16,850
Total stockholders' equity (deficiency)	229		-5,616
Total liabilities and stockholders' deficiency	3,051		723
Series A-1 Preferred stock [Member]
STOCKHOLDERS' EQUITY (DEFICIENCY):
Stock capital - Preferred stock		[1]		[1]
Series A-2 Preferred stock [Member]
STOCKHOLDERS' EQUITY (DEFICIENCY):
Stock capital - Preferred stock		[1]		[1]
Series B-1 Preferred stock [Member]
STOCKHOLDERS' EQUITY (DEFICIENCY):
Stock capital - Preferred stock	1
Series B-2 Preferred stock [Member]
STOCKHOLDERS' EQUITY (DEFICIENCY):
Stock capital - Preferred stock	2
Series C Preferred stock [Member]
STOCKHOLDERS' EQUITY (DEFICIENCY):
Stock capital - Preferred stock		[1]
[1]	Represents an amount lower than $ 1 thousands.

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Common stock, par value	$0.00	$0.00
Common stock, authorized	24,000,000	24,000,000
Common stock, issued	380,247	163,580
Common stock, outstanding	380,247	163,580
Series A-1 Preferred stock [Member]
Preferred stock, par value	$0.00	$0.00
Preferred stock, authorized	400,000	400,000
Preferred stock, issued	222,620	222,620
Preferred stock, outstanding	222,620	222,620
Series A-2 Preferred stock [Member]
Preferred stock, par value	$0.00	$0.00
Preferred stock, authorized	300,000	300,000
Preferred stock, issued	171,612	171,612
Preferred stock, outstanding	171,612	171,612
Series B-1 Preferred stock [Member]
Preferred stock, par value	$0.00	$0.00
Preferred stock, authorized	4,650,000	4,650,000
Preferred stock, issued	683,650	0
Preferred stock, outstanding	683,650	0
Series B-2 Preferred stock [Member]
Preferred stock, par value	$0.00	$0.00
Preferred stock, authorized	12,650,000	12,650,000
Preferred stock, issued	1,508,001	0
Preferred stock, outstanding	1,508,001	0
Series C Preferred stock [Member]
Preferred stock, par value	$0.00	$0.00
Preferred stock, authorized	5,500,000	5,500,000
Preferred stock, issued	833,333	0
Preferred stock, outstanding	833,333	0

CONSOLIDATED_STATEMENTS_OF_COM

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Income Statement [Abstract]
Revenues	$29	$62
Cost of revenues	10	22
Gross profit	19	40
Operating expenses:
Research and development	95	90
Selling and marketing	109	69
General and administrative	126	48
Total operating expenses	330	184
Operating loss	311	144
Financial expense, net	315	341
Loss before taxes on income	626	485
Taxes on income	4	18
Net loss	630	503
Total comprehensive loss	$630	$503
Net basic and diluted loss per share	($2.24)	($3.24)
Weighted average number of shares of Common stock used in computing basic and diluted net loss per share	281,543	155,009

CONSOLIDATED_STATEMENTS_OF_CHA

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (DEFICIENCY) (USD $)	Preferred stock		Common stock		Additional paid-in capital	Accumulated Deficit	Total
In Thousands, except Share data
Balance at Dec. 31, 2013		[1]		[1]	$10,906	($14,203)	($3,297)
Balance, Shares at Dec. 31, 2013	394,232		155,009
Stock-based compensation related to options granted to consultants and employees					3		3
Benefit component of convertible notes					52		52
Total comprehensive loss						-503	-503
Balance at Mar. 31, 2014		[1]		[1]	10,961	-14,706	-3,745
Balance, Shares at Mar. 31, 2014	394,232		155,009
Balance at Dec. 31, 2013		[1]		[1]	10,906	-14,203	-3,297
Balance, Shares at Dec. 31, 2013	394,232		155,009
Exercise of options				[1]				[1]
Exercise of options, Shares			8,571
Stock-based compensation related to options granted to consultants and employees					24		24
Benefit component of convertible notes				[1]	304		304
Total comprehensive loss						-2,647	-2,647
Balance at Dec. 31, 2014		[1]		[1]	11,234	-16,850	-5,616
Balance, Shares at Dec. 31, 2014	394,232		163,580
Issuance of Common stock, net of issuance costs				[1]	511		511
Issuance of Common stock, net of issuance costs, Shares			216,667
Issuance of Preferred C stock, net of issuance costs		[1]			1,964		1,964
Issuance of Preferred C stock, net of issuance costs, Shares	833,333
Issuance of warrants to Common stock					446		446
Conversion of Promissory Notes into Preferred B-1 stock and Preferred C stock	1				1,358		1,359
Conversion of Promissory Notes into Preferred B-1 stock and Preferred C stock, Shares	683,650
Conversion of Promissory Notes into Preferred B-2 stock and Preferred C stock	2				2,099		2,101
Conversion of Promissory Notes into Preferred B-2 stock and Preferred C stock, Shares	1,508,001
Issuance of warrants to consultant					84		84
Stock-based compensation related to options granted to consultants and employees					10		10
Total comprehensive loss						-630	-630
Balance at Mar. 31, 2015	$3			[1]	$17,706	($17,480)	$229
Balance, Shares at Mar. 31, 2015	3,419,216		380,247
[1]	Represents an amount lower than $ 1 thousands.

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Cash flows from operating activities:
Net loss	($630)	($503)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	2	2
Stock based compensation	10	3
Benefit component of Promissory Notes	285	75
Valuation of warrants to purchase Common stock	-25	32
Decrease (increase) in trade receivables	3	-1
Decrease in prepaid expenses and other accounts receivable	362	1
Decrease (increase) in inventories	6	-7
Increase (decrease) in accounts payable	-12	15
Decrease in other accounts payable	-357	-5
Decrease in accrued severance pay, net	-1
Accrued interest on Promissory Notes	58	231
Net cash used in operating activities	-299	-157
Cash flows from financing activities:
Proceeds from issuance of Common stock, Preferred stock and warrants, net of issuance costs	3,005
Proceeds from issuance of Promissory Notes and warrants		100
Net cash provided by financing activities	3,005	100
Increase (decrease) in cash and cash equivalents	2,706	-57
Cash and cash equivalents at the beginning of the period	90	94
Cash and cash equivalents at the end of the period	2,796	37
Supplemental information and disclosure of non-cash financing transactions:
Issuance costs		149
Conversion of Promissory Notes into Preferred B-1, B-2 stock and Preferred C stock	$3,457

GENERAL

GENERAL	3 Months Ended
	Mar. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GENERAL	NOTE 1:-	GENERAL
		a.	NanoVibronix, Inc. ("the Company"), a U.S. (Delaware) corporation, commenced operations on October 20, 2003 and is a medical device company focusing on noninvasive biological response-activating devices that target wound healing and pain therapy and can be administered at home, without the assistance of medical professionals.
	The Company's principal research and development activities are conducted in Israel through its wholly-owned subsidiary, Nano Vibronix (Israel 2003) Ltd., a company registered in Israel, which commenced operations in October 2003.
		b.	The Company’s ability to continue to operate is dependent mainly on its ability to successfully market and sell its products and the receipt of additional financing until profitability is achieved. During the three month period ended on March 31, 2015, the Company continued to incur losses and negative cash flows from operating activities amounting to $ 630 and $ 299, respectively.
		c.	On February 9, 2015, the Company filed a Registration Statement on Form 10 under the Securities Exchange Act of 1934, as amended, to register its Common stock under Section 12(g) of that act. The Form 10 was effective on April 10, 2015. See also Note 8b.

SIGNIFICANT_ACCOUNTING_POLICIE

SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	NOTE 2:-	SIGNIFICANT ACCOUNTING POLICIES
	The significant accounting policies applied in the annual consolidated financial statements of the Company as of December 31, 2014 are applied consistently in these financial statements.

UNAUDITED_INTERIM_FINANCIAL_ST

UNAUDITED INTERIM FINANCIAL STATEMENTS	3 Months Ended
	Mar. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
UNAUDITED INTERIM FINANCIAL STATEMENTS		NOTE 3:-	UNAUDITED INTERIM FINANCIAL STATEMENTS
	The accompanying unaudited condensed consolidated financial statements as of March 31, 2015 have been prepared in accordance with the U.S. generally accepted accounting principles for interim financial information. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles in the United States for complete financial statements. In the opinion of management, the unaudited interim consolidated financial statements include all adjustments of a normal recurring nature necessary for a fair presentation of the Company’s consolidated financial position as of March 31, 2015, the Company’s consolidated results of operation and the consolidated cash flows for the three months ended March 31, 2015. Results for the three months ended March 31, 2015 are not necessarily indicative of the results that may be expected for the year ended December 31, 2015.

FAIR_VALUE_MEASURMENTS

FAIR VALUE MEASURMENTS	3 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
FAIR VALUE MEASURMENTS		NOTE 4:-	FAIR VALUE MEASURMENTS
	ASC 820, "Fair Value Measurements and Disclosures" ("ASC 820"), defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions and risk of nonperformance.
	ASC 820 also establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. A financial instrument's categorization within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. ASC 820 establishes three levels of inputs that may be used to measure fair value.
		Level 1 -	quoted prices in active markets for identical assets or liabilities;
		Level 2 -	inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; or
		Level 3 -	unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets and liabilities.
	During February 2013, the Company signed a convertible Promissory Notes agreement ("The Agreement") and issued convertible Promissory Notes ("The Notes") to certain investors. In addition, the Company issued to the Note holders warrants to purchase 37,594 shares of Common stock. The exercise price at which the warrants may be exercised is $ 2.66 per share, subject to adjustment for stock splits, fundamental transactions or similar events including "down round" protection. The warrants expire within a period of five years, based on the issuance date.
	During February 2013 through December 2014, the Company had signed a second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth and fourteenth amendment to The Agreement, amended and restated the Notes with each amendment and issued warrants to purchase an additional 37,594 shares of Common stock per amendment in consideration for an additional $ 100 per amendment.
	As of December 31, 2014, the Company had issued a total of 563,910 warrants to purchase shares of Common stock to the holders of The Notes.
	The Company measures the warrants at fair value by applying the Black-Scholes option pricing model in each reporting period until they are exercised or expired, with changes in fair values being recognized in the Company’s consolidated statement of comprehensive loss as financial income or expense.
	In estimating the warrants' fair value, the Company used the following assumptions:
			Issuance date and
			March 31,
			2015
	Dividend yield (1)		0%
	Expected volatility (2)		63-67%
	Risk-free interest (3)		0.89-1.37%
	Expected term (years) (4)		3.25-4.25
		-1	Dividend yield - was based on the fact that the Company has not paid dividends to its stockholders in the past and does not expect to pay dividends to its stockholders in the future.
		-2	Expected volatility - was calculated based on actual historical stock price movements of companies in the same industry over a term that is equivalent to the expected term of the warrant.
		-3	Risk-free interest – was based on yield rate of non-index linked U.S. Federal Reserve treasury stock.
		-4	Expected term - was based on the maturity date of the warrants.
	Fair value measurement using significant unobservable inputs (Level 3):
			Fair value of
			warrants to
			Common stock
	Balance at January 1, 2015		$	734
	Change in fair value of warrants			(25	)
	Balance at March 31, 2015		$	709
	In addition, the Company’s financial instruments also include cash and cash equivalents, trade receivables, prepaid expenses and other accounts receivable, accounts payable and other accounts payable. The fair value of these financial instruments was not materially different from their carrying values as of March 31, 2015 due to the short-term maturities of such instruments.

STOCKHOLDERS_EQUITY_DEFICIENCY

STOCKHOLDERS' EQUITY (DEFICIENCY)	3 Months Ended
	Mar. 31, 2015
Stockholders' Equity Note [Abstract]
STOCKHOLDERS' EQUITY (DEFICIENCY)		NOTE 5:-	STOCKHOLDERS' EQUITY (DEFICIENCY)
		a.	In January and February 2015, the Company entered into securities purchase agreements with certain investors providing for the issuance of shares of Common stock, shares of Series C Preferred stock and warrants to purchase shares of Common stock. Pursuant to these agreements, the Company issued an aggregate of 833,333 shares of Series C Preferred stock, 216,667 shares of Common stock and warrants to purchase 420,000 shares of Common stock at an exercise price of $3.00 per share and warrants to purchase 420,000 shares of Common stock at an exercise price of $ 6.00 per share, for aggregate consideration of $ 3,005 net of issuance costs of $ 145, which were previously recorded as deferred issuance costs.
		b.	In February 2015, upon the receipt by the Company of investment amounts aggregating $ 3,150, as described above, the B-1 Promissory Notes converted by their terms into an aggregate of 560,594 shares of the Company's Series B-1 Preferred stock and 123,057 shares of Series C Preferred stock, and the Company's B-2 Promissory Notes converted by their terms into an aggregate of 1,174,042 shares of Series B-2 Preferred stock and 333,959 shares of Series C Preferred stock.

GEOGRAPHIC_INFORMATION_AND_MAJ

GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA	3 Months Ended
	Mar. 31, 2015
Segment Reporting [Abstract]
GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA		NOTE 6:-	GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA
	Summary information about geographic areas:
	The Company manages its business on the basis of one reportable segment, and derives revenues from selling its products directly to patients as well as through distributor agreements. The following is a summary of revenues within geographic areas:
			Three months ended
			March 31,
			2015		2014
	United States		$	16	$	28
	Europe			3		9
	Israel			-		6
	India			3		2
	Rest of the world			7		17
			$	29	$	62
	During the three month period ended March 31, 2015, revenues from a distributor accounted for 22% of total revenues. During the three month period ended March 31, 2014, revenues from a distributor accounted for 28% of total revenues.
	The Company's long-lived assets are all located in Israel.

RELATED_PARTY_TRANSACTIONS

RELATED PARTY TRANSACTIONS	3 Months Ended
	Mar. 31, 2015
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS		NOTE 7:-	RELATED PARTY TRANSACTIONS
		a.	On March 25, 2015, the Company entered into an employment agreement with its chief executive officer.  Under this employment agreement, he is entitled to a fee based on sales of the Company’s PainShield product in the United States or Canada during the term of the employment agreement.
		b.	On March 25, 2015, the Company issued warrants to purchase up to 61,000 shares of Common stock to a related party as consideration for the provision of guidance and assistance in connection with the filing of the Company’s Form 10 and becoming a public reporting company.  The warrants have an exercise price of $2.57 per share, subject to adjustment.
		c.	On March 25, 2015, the Company entered into an agreement with a member of the board of directors, pursuant to which, as consideration for his efforts developing, pursuing approval of, and/or raising market awareness and acceptance of the Company’s vibrating urology catheter-related products, the director is entitled to a fee for all such products sold in the United States or Canada during the term of the agreement.  At the Company’s option, the fee may be paid in the form of cash or shares of Common stock. If paid in cash, the director must use a portion of the fee to purchase shares of Common stock in the open market within 30 days, subject to any limitations or restrictions that may apply under applicable laws.

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	3 Months Ended
	Mar. 31, 2015
Subsequent Events [Abstract]
SUBSEQUENT EVENTS		NOTE 8:-	SUBSEQUENT EVENTS
		a.	In April 2015, subsequent to the balance sheet date, the holders of the Fifteenth Amended and Restated Secured Convertible Promissory Notes elected to convert the outstanding principal and interest thereunder into 603,769 shares of the Company's Series C Preferred stock.
		b.	In April 2015, subsequent to the balance sheet date, upon the effectiveness of the Company's Form 10 filed with the Securities and Exchange Commission, the outstanding shares of Series A-1 Preferred stock,  Series A-2 Preferred stock,  Series B-1 Preferred stock and  Series B-2 Preferred stock converted by their terms into 2,131,081 shares of  Common stock.
		c.	In April 2015, subsequent to the balance sheet date, the Company issued 100,000 shares of Common stock to its legal counsel as part of the total consideration for its legal services associated with the Company’s fund raising.
		d.	The Company evaluates events or transactions that occur after the balance sheet date but prior to the issuance of financial statements to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. For its interim consolidated financial statements as of March 31, 2015 (unaudited) and for the three month period then ended (unaudited), the Company evaluated subsequent events through May 14, 2015 the date that the consolidated financial statements were issued.

FAIR_VALUE_MEASURMENTS_Tables

FAIR VALUE MEASURMENTS (Tables)	3 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Estimating the warrants' fair value	In estimating the warrants' fair value, the Company used the following assumptions:
		Issuance date and
		March 31,
		2015
	Dividend yield (1)	0%
	Expected volatility (2)	63-67%
	Risk-free interest (3)	0.89-1.37%
	Expected term (years) (4)	3.25-4.25
Fair value measurement using significant unobservable inputs (Level 3)	Fair value measurement using significant unobservable inputs (Level 3):
		Fair value of
		warrants to
		Common stock
	Balance at January 1, 2015	$	734
	Change in fair value of warrants		(25	)
	Balance at March 31, 2015	$	709

GEOGRAPHIC_INFORMATION_AND_MAJ1

GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Tables)	3 Months Ended
	Mar. 31, 2015
Segment Reporting [Abstract]
Summary of revenues within geographic areas	The following is a summary of revenues within geographic areas:
		Three months ended
		March 31,
		2015		2014
	United States	$	16	$	28
	Europe		3		9
	Israel		-		6
	India		3		2
	Rest of the world		7		17
		$	29	$	62

GENERAL_Details_Narrative

GENERAL (Details Narrative) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net loss	$630	$503
Net cash used in operating activities	$299	$157
Operation commenced date	20-Oct-03
Description of company	The Company's principal research and development activities are conducted in Israel through its wholly-owned subsidiary, Nano Vibronix (Israel 2003) Ltd., a company registered in Israel, which commenced operations in October 2003.

FAIR_VALUE_MEASURMENTS_Details

FAIR VALUE MEASURMENTS (Details) (Warrants [Member])	3 Months Ended
	Mar. 31, 2015
Dividend yield	0.00%	[1]
Minimum [Member]
Expected volatility	63.00%	[2]
Risk-free interest	0.89%	[3]
Expected term (years)	3 years 3 months	[4]
Maximum [Member]
Expected volatility	67.00%	[2]
Risk-free interest	1.37%	[3]
Expected term (years)	4 years 3 months	[4]
[1]	Dividend yield - was based on the fact that the Company has not paid dividends to its stockholders in the past and does not expect to pay dividends to its stockholders in the future.
[2]	Expected volatility - was calculated based on actual historical stock price movements of companies in the same industry over a term that is equivalent to the expected term of the warrant.
[3]	Risk-free interest - was based on yield rate of non-index linked U.S. Federal Reserve treasury stock.
[4]	Expected term - was based on the maturity date of the warrants.

FAIR_VALUE_MEASURMENTS_Details1

FAIR VALUE MEASURMENTS (Details 1) (Warrants [Member], USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015
Warrants [Member]
Balance at January 1, 2015	$734
Change in fair value of warrants	-25
Balance at March 31, 2015	$709

FAIR_VALUE_MEASURMENTS_Details2

FAIR VALUE MEASURMENTS (Details Narrative) (USD $)	1 Months Ended	3 Months Ended		23 Months Ended
In Thousands, except Share data, unless otherwise specified	Feb. 28, 2013	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Mar. 25, 2015	Jan. 31, 2015
Fair Value Disclosures [Abstract]
Issued warrant to purchase of common stock	37,594			563,910	61,000	420,000
Warrant exercise price	$2.66				$2.57	$6
Warrant expiration period	5 years
Proceeds from issuance of Promissory Notes and warrants			$100	$100

STOCKHOLDERS_EQUITY_DEFICIENCY1

STOCKHOLDERS' EQUITY (DEFICIENCY) (Details Narrative) (USD $)	1 Months Ended	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Jan. 31, 2015	Mar. 31, 2015	Mar. 31, 2014	Mar. 25, 2015	Feb. 28, 2015	Dec. 31, 2014	Feb. 28, 2013
Common stock shares issued	216,667	380,247				163,580
Common stock shares issued exercise price	$3
Issued warrant to purchase of common stock	420,000			61,000		563,910	37,594
Warrant to purchase of common stock exercise price	$6			$2.57			$2.66
Proceeds from issuance of sale of equity	$3,005	$3,005
Issuance costs net	145
Promissiory note aggregate investment amount					$3,150
Series C Preferred Stock [Member]
Common stock shares issued	833,333
Convertible stock					123,057
Series B-1 Preferred stock [Member]
Convertible stock					560,594
Series B-2 Preferred stock [Member]
Convertible stock					1,174,042
Series C Preferred stock One [Member]
Convertible stock					333,959

GEOGRAPHIC_INFORMATION_AND_MAJ2

GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Revenues	$29	$62
United States [Member]
Revenues	16	28
Europe [Member]
Revenues	3	9
Israel [Member]
Revenues		6
India [Member]
Revenues	3	2
Rest of the world [Member]
Revenues	$7	$17

GEOGRAPHIC_INFORMATION_AND_MAJ3

GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Details Narrative)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Segment Reporting [Abstract]
Revenues from a distributor accounted	22.00%	28.00%

RELATED_PARTY_TRANSACTIONS_Det

RELATED PARTY TRANSACTIONS (Details Narrative) (USD $)	Mar. 25, 2015	Jan. 31, 2015	Dec. 31, 2014	Feb. 28, 2013
Related Party Transactions [Abstract]
Warrants issued to purchase of common stock	61,000	420,000	563,910	37,594
Exercise price of warrants	$2.57	$6		$2.66

SUBSEQUENT_EVENTS_Details_Narr

SUBSEQUENT EVENTS (Details) (Narrative)	3 Months Ended	1 Months Ended
	Mar. 31, 2015	Apr. 30, 2015
Common stock [Member]
Conversion of outstanding principal and interest
Subsequent Event [Member] | Common stock [Member]
Outstanding shares of Series A-1 Preferred stock, Series A-2 Preferred stock, Series B-1 Preferred stock and Series B-2 Preferred stock converted		2,131,081
Shares issued in consideration of legal services		100,000
Subsequent Event [Member] | Series C Preferred Stock [Member]
Conversion of outstanding principal and interest		603,769